Farmas USA

Sangamo up 6% premarket on Gilead deal to develop oncology-focused cell therapies

https://seekingalpha.com/news/3333236-sangamo-6-percent-premarket-gilead-deal-develop-oncology-focused-cell-therapies

Assessing Chances Of Success For Arena Pharmaceutical's Highly Anticipated Etrasimod P2 Results

To give you an idea of the value of this sector look at the $7.2 billion that Celgene paid in 2015 to acquire Receptos, primarily to get its hands on Ozanimod which Receptos was then developing.

https://seekingalpha.com/article/4149325-assessing-chances-success-arena-pharmaceuticals-highly-anticipated-etrasimod-p2-results?app=1&auth_param=7ib4d:1d8tft2:d7fb9840899a3ba6547aed568a5fee0f&uprof=44

ACOR

Noticia de hace 2 días

FDA Acceptance of New Drug Application for INBRIJA™ (levodopa inhalation powder)

The NDA for INBRIJA includes data from a Phase 3 safety and efficacy study (SPAN-PD), as well as results from two long-term safety studies in people with Parkinson’s disease. Findings from these studies support the filing of INBRIJA for use on an as-needed basis to address symptoms of OFF periods in patients on a carbidopa/levodopa regimen. Data from the SPAN-PD trial were presented at the International Congress of Parkinson’s Disease and Movement Disorders (MDS) in June 2017.

http://ir.acorda.com/investors/investor-news/investor-news-details/2018/Acorda-Announces-FDA-Acceptance-of-New-Drug-Application-for-INBRIJA-levodopa-inhalation-powder/default.aspx

ADXS puesta en modo chicharro .....de momento a observar , y recopilar más datos, para afinar la mejor posible entrada , que no es nada fácil , ya que perdidos los 2 , puede iniciar trayecto muy peligroso hacia un valor que mejor no pongo por respeto a los que están dentro ....( en esta ocasión , el sistema ha funcionado con las oportunas alertas de No entradas...pero sinceramente , me ha costado mucho no sucumbir a la tentación ....ànimo a los que estáis dentro , que el año es largo y espero que recupere un valor digno 😉)

ADXS

Offering 10 millones a 2 $.

 30-day option to purchase up to 807,697 additional shares of Advaxis common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about February 26, 2018

https://www.streetinsider.com/Corporate+News/Advaxis+%28ADXS%29+Prices+10M+Offering+of+Common+Stock+at+%242Share/13850579.html

OMER

Fuera en apertura

ADXS

Otras pocas a 2$, me guardo último tiro para 1.50-1.60

Según comenta Roy Friedman, en 1H 2018 se esperan news del programa que tienen con AMGN (NEO program). Que es lo más destacable de ADXS en estos momentos

ACHN

la tiran a 2,70 y de repente en un parpadeo ...patadon pa'rriba 20 centavos ...